Drugs / EV71

Trials 1

2020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 4 NCT04133584 Sep 2019 → Jun 2021 hand, foot and mouth disease, influenza Zhejiang Provincial Center for Disease Control and Prevention Completed No outcome recorded

News releases announcing trial results or a regulatory action · 5

DateIssuerRelease
2026-03-17 Medigen Vaccine Biologics Corp. Regulatory 高端恩穩健成功取得越南首張腸病毒71型疫苗藥證,攜手Substipharm Biologics拓展東南亞商業布局 medigenvac.com ↗
高端疫苗生物製劑股份有限公司(MVC)與 Substipharm Biologics 今日 (2026/03/17) 共同宣布,恩穩健(ENVACGEN®)腸病毒71型(EV-A71)疫苗已正式取得越南藥品管理局(DAV)核發之藥品上市許可。
2024-12-19 Medigen Vaccine Biologics Corp. Results 越南巴斯德與高端疫苗共同舉辦腸病毒專家會議 獲得廣大迴響 medigenvac.com ↗
本次臨床試驗的疫苗組中皆無確診個案,且疫苗統計學有效性高達96.8%,試驗結果發表於國際權威醫學期刊《刺胳針》(The Lancet),證明這支疫苗除具備豐富的實證醫學數據,也是越南當地臨床試驗的重要標竿。
2023-07-06 Institute of Vaccines and Medical Biologicals, Vietnam Results Việt Nam sắp có vaccine tay chân miệng ngừa chủng nguy hiểm nhất com.vn ↗
ghi nhận vaccine giúp bảo vệ trẻ chống lại bệnh tay chân miệng do EV71 ở bất kỳ độ nặng nào, hiệu quả 96,8%.
2021-04-11 Medigen Vaccine Biologics Corp. Results 高端疫苗「腸病毒71型疫苗」多國多中心三期臨床試驗,免疫數據解盲 medigenvac.com ↗
高端腸病毒71型疫苗三期臨床試驗,於台灣及越南完成超過3,000人收案,在進一步完成受試者施打一年後的血清檢體採集、及實驗室數據分析後,於110年4月10日完成免疫生成性數據解盲,且數據達到台灣法規單位建議標準。
2019-03-21 Medigen Vaccine Biologics Corp. Regulatory 高端疫苗腸病毒EV71型疫苗 全球首獲越南衛生部核准3期臨床試驗 medigenvac.com ↗
本公司之腸病毒71型疫苗於今(3/21)日獲越南衛生部(Ministry of Health of Vietnam)核准進行第三期臨床試驗,加上先前已取得之台灣衛福部核准,本公司腸病毒71型疫苗將展開多國多中心第三期臨床試驗,台、越兩地總收案人數為3,000~3400人,可望於今年完成收案。

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as EV71 ClinicalTrials.gov intervention name — accepted as the source's own label NCT04133584 ↗
Known as Inactivated Enterovirus 71 Vaccine “Inactivated Enterovirus 71 Vaccine (EV71)” NCT04133584 ↗
Modality Vaccine “Inactivated Enterovirus 71 Vaccine (EV71)” NCT04133584 ↗